Spots Global Cancer Trial Database for Rapamycin in Relapsed Acute Lymphoblastic Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Rapamycin in Relapsed Acute Lymphoblastic Leukemia

Official Title: Rapamycin in Relapsed Acute Lymphoblastic Leukemia

Study ID: NCT00874562

Conditions

Acute Lymphoblastic Leukemia

Interventions

Corticosteroid

Rapamycin

Study Description

Brief Summary: This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used alone or with another drug called rapamycin. Rapamycin is a drug that prevents the body's immune system from working normally. It has been used for many years after kidney transplants to prevent rejection of the organ. Recent work suggests that rapamycin may also help treat leukemia and other cancers.

Detailed Description: * Participants will be randomized into two groups; one group will receive corticosteroid alone, and the other group will receive rapamycin and corticosteroid. * The length of treatment will be 5 days, during which time we will collect blood samples to measure the biologic effects of these drugs. Because these drugs will be given for a short period of time only, this study is not designed to treat or cure the participants leukemia. After the 5-day period, participants may resume other cancer-directed therapies.